Taisho Pharmaceutical Co., Ltd.: Biolinq Raises $58 Million to Advance Wearable Biosensors Through Pivotal Trial for Metabolic Health Using Precision Microsensor Technology

Biolinq Incorporated announced the completion of $58 million in financing led by Alpha Wave Ventures, with participation from Niterra's corporate venture capital fund jointly operated with Pegasus Tech Ventures and existing investors RiverVest Venture Partners, AXA IM Alts, Global Health Investment Corporation, Aphelion Capital, Senvest Management, Features Capital and Taisho Pharmaceutical.